10:50 AM
Jan 12, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Innovation's Brilacidin-OM meets in Phase II for oral mucocitis

Innovation Pharmaceuticals Inc. (OTCQB:IPIX) reported top-line data from 46 patients receiving chemoradiation for head and neck cancer in the modified intent-to-treat (mITT) population of a Phase II trial showing that thrice-daily 45 mg/15...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >